Himanshu K Mishra, Heather Wei, Kayla E Rohr, Insu Ko, Caroline M Nievergelt, Adam X Maihofer, Paul D Shilling, Martin Alda, Wade H Berrettini, Kristen J Brennand, Joseph R Calabrese, William H Coryell, Mark Frye, Fred Gage, Elliot Gershon, Melvin G McInnis, John Nurnberger, Ketil J Oedegaard, Peter P Zandi, John R Kelsoe, Michael J McCarthy
Bipolar disorder (BD) is characterized by mood episodes, disrupted circadian rhythms and gray matter reduction in the brain. Lithium is an effective pharmacotherapy for BD, but not all patients respond to treatment. Lithium has neuroprotective properties and beneficial effects on circadian rhythms that may distinguish lithium responders (Li-R) from non-responders (Li-NR). The circadian clock regulates molecular pathways involved in apoptosis and cell survival, but how this overlap impacts BD and/or lithium responsiveness is unknown...
April 29, 2023: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology